Investing for a healthier future

Whether you are an investor seeking impactful returns or an entrepreneur looking to take your business to the next level, Sciety is your go-to partner

Our latest news

The rise of peptide-based pharmaceuticals

INSIGHT. Peptides (short chains of amino acids) have long been used in the development of pharmaceuticals, such as diabetes medicine. In recent years, we’ve seen a dramatic increase in peptide-based pharmaceuticals.  In 2022, peptide pharmaceuticals accounted for 5 percent of

Read more

Are you searching for the next big thing in life science and health tech?

Your search ends here. By joining Sciety Venture Partners, you have the opportunity to invest alongside Sciety in the most promising life science companies. Not only do you benefit from our extensive research and expertise, but you also become part of a network of like-minded investors.

Let us make health and life science innovations reach their full potential. Sign up to join Sciety Venture Partners and start receiving invitations to investor events, investment opportunities and news.

Yes, please keep me in the loop

Tell me more first

Sciety Venture Partners comprises private investors, family offices and venture capital firms. Among the members are professionals with extensive experience in the life science field, for example as researchers, entrepreneurs, or investors. We interviewed some of our members and asked why they choose to invest in and support unlisted companies in life science.

Lots of opportunities, lots to be done

Sweden takes the lead

Sweden is Northern Europe’s most dynamic market for life sciences, with a strong focus on innovation and collaboration. It is in the top five among the world’s countries in terms of investment in research and development.

Long-term demand

An aging population, increasing incidence of lifestyle diseases, and more demanding health care consumers are increasing demand for drugs, innovative medical technology, and digital solutions.

Precision medicine and genomics

The biotechnological revolution creates new opportunities to develop customized treatments for each individual disease case. This in turn leads to increased demand for precision diagnostics and technology solutions in areas such as genomics.

Growth companies on top

Growth companies in the biopharma sector are behind the majority of all new drugs approved by the FDA. Increasing numbers of partnership agreements are also being signed between Big Pharma and smaller companies.

More tech in healthcare

Digital solutions are being implemented at a fast pace. Efforts to streamline healthcare processes, cost savings, and improved health care quality as well as increased demand for on-demand care are drivers behind this trend.

Life saving advancements

Over the past 100 years, the global average life expectancy has more than doubled and is now 73 years. The child mortality rate in the world has declined by nearly 75% since 1950. Significant medical advances are one of the causes behind this positive development.

Are you looking for an investor that will support you in turning your life science or health tech innovation into a thriving business?

We’ve got you covered.

At Sciety, we understand that securing an investment is just the first step in building a successful company. That is why our investment is more than just financial capital – it is a long-term partnership.

Our team of experts, including researchers, clinicians, entrepreneurs, and business professionals, brings a unique combination of skills to the table. We are dedicated to helping you reach your full potential and will be by your side every step of the way. Want to learn more?

Yes, please keep me posted about news and invitations

Sounds interesting, tell me more

Companies we are investing in right now​

Learn more about our ongoing investments. We have made our analysis, negotiated the terms and made our decision. We have compiled the information and documents for you to make your decision.

DB Evidence

Evidence has developed a unique SaaS solution with AI functionality, specifically designed for healthcare. Evidence helps management optimize resource use and improve care quality by consolidating all critical functions into a single system.

Read more

Companies we are investing in right now

We are currently investing in one or more companies that passed our rigorous selection process. Please login or create an account to learn more and co-invest with us.

Some of our portfolio companies

Capitainer AB

Capitainer develops and sells intelligent solutions for self-sampling blood, plasma, and urine. The products enable easy home sampling with market-leading precision, delivering value across the entire care chain.

Pharmnovo AB

PharmNovo is a pharmaceutical company at the clinical stage of developing a unique type of treatment for nerve pain (neuropathic pain), a condition currently lacking effective and safe treatment. The company is currently finalising its clinical phase I study and is advancing its preparations for a phase II study.

Neogap Therapeutics AB

NEOGAP Therapeutics develops a new type of personalised therapy for the treatment of cancer. The company uses proprietary machine learning algorithms and patented technology to tailor the treatment for each patient and its specific tumour cells.

Encare AB

Encare not only contributes to more cost-effective surgery but also reduces complications and saves lives through their proprietary software solution that helps hospitals implement best practice throughout the entire care chain – from diagnosis and preparation to surgery and rehabilitation.